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Phenotypic high-throughput chemical screens allow
for discovery of small molecules that modulate com-
plex phenotypes and provide lead compounds for
novel therapies; however, identification of the mech-
anistically relevant targets remains a major exper-
imental challenge. We report the application of
sequential unbiased high-throughput chemical and
ultracomplex small hairpin RNA (shRNA) screens to
identify a distinctive class of inhibitors that target
nicotinamide phosphoribosyl transferase (NAMPT),
a rate-limiting enzyme in the biosynthesis of nicotin-
amide adenine dinucleotide, a crucial cofactor in
many biochemical processes. The lead compound
STF-118804 is a highly specific NAMPT inhibitor,
improves survival in an orthotopic xenotransplant
model of high-risk acute lymphoblastic leukemia,
and targets leukemia stem cells. Tandem high-
throughput screening using chemical and ultracom-
plex shRNA libraries, therefore, provides a rapid
chemical genetics approach for seamless progres-
sion from small-molecule lead identification to target
discovery and validation.
INTRODUCTION
Cell-based high-throughput chemical screens (HTSs) are a
powerful approach for the discovery of small molecules that
modulate complex phenotypes, such as viability, and may serve
as leadcompounds for thedevelopment of novel therapies. How-1352 Chemistry & Biology 20, 1352–1363, November 21, 2013 ª2013ever, subsequent identification of the cognate target or pathway
through which the compound acts remains technically chal-
lenging, and lack of understanding of the mechanism of action
is a roadblock for drug development. Thus, efforts have shifted
away from phenotypic screening to in vitro target-based
screening approaches. Although the latter are leveraged on an
understanding of the mechanism of action, the biological
hypothesis is often not confirmed, the target may not be ‘‘drug-
gable,’’ and the discovered molecules may not affect the
desired phenotype. Furthermore, despite a major shift to
‘‘target-centric’’ approaches for drug discovery, the Food and
Drug Administration, over a recent 10-year period (1999–2008),
approved more first-in-class new molecular entities (NMEs) that
were identified via phenotypic screening (28 NMEs) than target-
based approaches (18 NMEs) (Swinney and Anthony, 2011). As
a consequence, phenotypic screening is experiencing a resur-
gence indrugdiscovery, despite persistent challengespresented
by target identification (Kotz, 2012; Schenone et al., 2013).
Currently, target identification can be accomplished through
molecule-target immobilization followed by chemical prote-
omics (Fleischer et al., 2010; Ong et al., 2009), pattern matching
techniques utilizing gene expression profiling (Lamb, 2007;
Lamb et al., 2006), and NCI-60 sensitivity (Huang et al., 2005;
Paull et al., 1989; Weinstein et al., 1997), or a combination of
these techniques (Hahn et al., 2009; Stegmaier et al., 2005).
Each of these approaches as currently applied, however, has
limitations and technical challenges. Genetic approaches using
shRNA screens have been used to understand the genetic path-
ways involved in mechanisms of action of known chemothera-
peutic agents (Brummelkamp et al., 2006; Burgess et al., 2008;
Luo et al., 2008; Tsujii et al., 2010) but have yet to be used to
identify the target of an unknown agent. Functional genomic
approaches based on shRNA screens have been limited by the
breadth and depth of coverage of available libraries. Recently,Elsevier Ltd All rights reserved
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Figure 1. Phenotypic Chemical HTS Screen
Identifies a Class of Cytotoxic Compounds
(A) Schematic summary of the experimental
approach used for a phenotypic, cell-based, high-
throughput, small molecule screen and sub-
sequent confirmatory analyses that identified lead
compound STF-118804, which inhibited human
ALL cell lines with nanomolar potency. Structurally
related analogs were tested to determine SAR of
STF-118804.
(B) Human B-ALL cell lines were treated with STF-
118804 (upper graph) or idarubicin (lower graph)
and assessed for viability at day 3 via CellTiter-
Blue. Data are from three independent experi-
ments performed in triplicate (±SEM).
(C) Chemical structure of STF-118804.
(D) Viability of MV411 cells was quantified after
3-day culture in the presence of the indicated
structural analogs of STF-118804. Data represent
three independent experiments performed in trip-
licate (±SEM).
(E) Chemical structures are shown for represen-
tative STF-118804 analogs.
See also Figure S1 and Table S1.
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Chemical Genetic Discovery of NAMPT Inhibitorsthis limitation has been addressed by engineering ultracomplex
shRNA libraries that target the entire human genome with 25
shRNAs per gene (Bassik et al., 2013) and contain thousands
of negative control shRNAs. This allows for RNAi-based, pooled
screening of thousands of shRNAs for a specific phenotype that
can be monitored by deep sequencing and significantly reduces
both false-negative and false-positive rates by identifying hit
genes based on the comparison between the distribution of phe-
notypes observed for shRNAs targeting each gene and the dis-
tribution of negative control shRNAs. This approach is extremely
effective in identifying genes that confer sensitivity or resistance
to a drug or toxin using survival-based assays (Bassik et al.,
2013) and, thus, potentially useful in identifying target genes
for drugs with an unknown mechanism of action.
There is a critical need for new agents with novel therapeu-
tic targets and improved safety profiles in cancer treatment.
This is particularly the case for high-risk and relapsed acuteChemistry & Biology 20, 1352–1363, November 21, 2013 ªlymphoblastic leukemia (ALL), which is
a significant cause of morbidity and mor-
tality in pediatric and adult populations
(Pui et al., 2008). Although significant
advances have been made in treatment,
high-risk ALL continues to pose signif-
icant therapeutic challenges. Cytotoxic
agents remain the standard of care for
acute leukemia, and for decades, ther-
apies have relied on similar regimens.
Despite numerous efforts to improve
treatments with new drug combinations,
these approaches have reached a point
of diminishing returns, since intensified
chemotherapies contribute only mar-
ginal improvement in outcome and
display increased toxicity with long-
term sequelae.We report the use of a chemical genetics approach to identify
small molecules active in ALL and their targets. We performed
sequential unbiased high-throughput phenotypic chemical and
ultracomplex, genome-scale shRNA screens to identify a
distinctive class of inhibitors that target nicotinamide phosphor-
ibosyl transferase (NAMPT), a rate-limiting enzyme in the salvage
pathway for biosynthesis of nicotinamide adenine dinucleotide
(NAD+), a crucial cofactor in many biological and biochemical
processes.
RESULTS
Identification of Cytotoxic Compounds Active in ALL
by HTS
A cell-based phenotypic HTS was conducted using B-ALL cell
lines to identify compounds with potential selective antileukemic
properties (Figure 1A). Screening of 115,000 compounds in HTS2013 Elsevier Ltd All rights reserved 1353
Table 1. Inhibitory Concentrations for STF-118804 and
Idarubicin on Cell Lines, Patient Samples, and Normal
Progenitors
Cell type
STF-118804 IC50
(nM) (±95% CI)
Idarubicin IC50
(nM) (±95% CI)
SEM 2.7 (2.3–3.2) 1.0 (0.4–2.4)
KP-Y-RL 2.6 (1.9–3.4) 11.4 (6.8–19.2)
MV411 6.0 (5.2–7.0) 7.6 (3.9–14.9)
Nalm6 8.8 (8.0–9.8) 4.6 (2.8–7.5)
697 8.6 (7.5–9.8) 7.6 (4.3–13.4)
Hal01 9.2 (8.1–10.5) 3.2 (1.9–5.4)
REH >10,000 1.5 (0.7–5.4)
SUP-B15 >10,000 2.8 (1.0–7.5)
MLL-AF4 patient 1 13.9 (6.3–31.1) ND
MLL-AF4 atient 2 32.3 (13.3–78.3) ND
MLL-AF4 patient 3 3.1 (1.1–29) ND
MLL-AF4 patient 4 5.1 (1.3–20.1) ND
TEL-AML patient 5 4.2 (3.1–5.6) ND
Lin cord blood cells 40.2 (19.6–82.5) 11.1 (7.5–16.7)
c-kit+ murine BM 62.3 (52.1–74.5) 11.5 (9.0–14.6)
Cells were incubated with increasing concentrations of STF-118804 or
idarubicin, and viability was assessed using CellTiter-Blue or WST-1 re-
agent. Assays were performed in triplicate, and IC50 was calculated using
Prism or CalcuSyn software. ND, not determined.
Chemistry & Biology
Chemical Genetic Discovery of NAMPT Inhibitorsformat used ametabolic assay of viability based on redox reduc-
tion of resazurin (CellTiter-Blue). Six hundred forty initial prelim-
inary ‘‘hits’’ were identified that reduced viability of one or both
ALL cell lines with high-risk genetic abnormalities of the MLL
gene (RS411 and HB) by more than 30% but did not inhibit the
growth of a cell line lacking MLL rearrangement (REH). Com-
pounds that affected all three cell lines, such as the anthracycline
idarubicin, were excluded from further analysis. Initial candi-
dates (640) were retested for their dose-dependent toxicity to
yield 86 validated compounds with selective properties. The
most potent and selective 64 were reordered and tested on an
expanded panel of eight human B-ALL cell lines to identify lead
compound STF-118804, whose structure (Figure 1C) was veri-
fied by nuclear magnetic resonance (NMR) analysis and mass
spectrometry (data not shown).
STF-118804 reduced the viability of most B-ALL cell lines with
high potency demonstrating half maximal inhibitory concentration
(IC50) values in the low nanomolar range (Table 1). Cell lines with
thehighest sensitivity (SEMandKP-Y-RL)containedMLLchromo-
somal translations, whereas two non-MLL cell lines (REH and
SUP-B15) were resistant (Figure 1B). While the increased sensi-
tivity may not be clinically relevant, it suggested specificity. Idaru-
bicin, which nonspecifically intercalates into DNA, affected all cell
lines in the low nanomolar range without selectivity (Figure 1B;
Table 1). Leukemic samples from five pediatric ALL patients
were also sensitive to STF-118804 in the low nanomolar range
(Table 1). The lead compound displayed 5- to 10-fold more
potency against most leukemias in comparison to cycling human
(lineage-negative cord blood) and murine (c-kit+ BM) progenitor
cells (Table 1; Figure S1 available online), a therapeutic index
considerably larger than that of idarubicin, a drug with known1354 Chemistry & Biology 20, 1352–1363, November 21, 2013 ª2013efficacy used in ALL therapy. Thus, HTS identified a promising
leadcompoundwithpotentially selectiveanti-leukemicproperties.
Structure activity relationship was assessed for 112 structur-
ally related analogs of STF-118804 in HTS format for their ability
to inhibit the in vitro growth of four ALL cell lines. Five represen-
tative analogs were individually retested for their toxicity on leu-
kemia cell line MV411 (Figures 1D and 1E; Table S1). These
studies identified STF-118804 as a potent representative of a
distinct class of cytotoxic compounds and defined chemical
subgroups critical for its potency and toxicity.
STF-118804 Induces Leukemia Cell Apoptosis without
Antecedent Cell Cycle Arrest
MV411 cells treated with STF-118804 proliferated for 24 hr com-
parable with the vehicle control (Figure 2A) but were markedly
decreased in number at 36 hr. This correlated with the onset of
apoptosis as quantified by flow cytometry for annexin-V-positive
cells (Figure 2B) and the presence of cleaved PARP at 36 hr (but
not 24 hr) in western blot analysis (Figure 2D). At 48 hr, the vast
majority of MV411 cells were nonviable, as evidenced by propi-
dium iodide staining (Figure 2B).
Cell cycle analysis based on DNA content confirmed that
MV411 cells continued to cycle and did not arrest before the
onset of apoptosis (appearance of sub-G0 population) at 36 hr
of treatment (Figure 2C). This contrasted with idarubicin, which
induced rapid cell cycle arrest (24 hr) characterized by a
decreased percentage of cells in the G1 and S phases and an
accumulation of cells in the G2/M phase (Figure 2C). Therefore,
STF-118804 displays distinctive cytotoxicity by inducing
apoptosis without causing a phase-specific cell cycle arrest.
Assessment of cell viability following treatment with STF-
118804 using a live cell protease activity assay (CellTiter-Fluor)
gave results equivalent to those of the resazurin-based assay
(CellTiter-Blue) (Figure 2E), confirming that the latter provided a
reasonable measure of cell viability in the HTS and validation
studies.
In an NCI-60 cell line panel screen, STF-118804 showed po-
tency in various cancer cells including high selectivity for colon
and prostate cell lines (Figure S2), suggesting broader applica-
tions beyond leukemia. Comparison of the STF-118804 sensi-
tivity profile to known chemotherapeutic agents in the National
Cancer Institute (NCI) database (NCI COMPARE) showed no sig-
nificant overlap, indicating that STF-118804 functions through a
unique mode of action.
Functional Genomic shRNA Screen Identifies NAMPT as
a Candidate Target for STF-118804
To discover themolecular target of STF-118804, we performed a
functional genomic screen to identify shRNAs that conferred
sensitivity or resistance to STF-118804 (Figure 3A). MV411 cells
were transduced with pooled sublibraries of shRNAs from a high
coverage (25 shRNA per gene) library targeting in total 9,300
human genes and including 500 or more negative control
shRNAs per sublibrary (Bassik et al., 2013). Stably transduced
cells were subjected to four rounds of treatment with increasing
concentrations of STF-118804 or four rounds of mock treatment.
Several shRNAs targeting the gene NAMPT were markedly
depleted in the STF-118804-treated population compared to
control shRNAs (Figure 3B), indicating that shRNAs againstElsevier Ltd All rights reserved
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Figure 2. STF-118804 Induces Apoptosis without Antecedent Cell Cycle Arrest
(A) Growth of MV411 cells in the absence or presence of STF-118804 (100 nM) or idarubicin (25 nM) was quantified by trypan blue exclusion. Errors bars represent
SEM for three independent experiments.
(B) MV411 cells were treatedwith STF-118804 (100 nM) for the indicated times and assessed by flow cytometry for annexin V-FITC and propidium iodide staining.
Double-positive cells correspond to late stages of apoptosis. Data are representative of three independent experiments.
(C) Cell cycle statuswas assessed by propidium iodide staining ofMV411 cells treated or untreated for the indicated timeswith STF-118804 (100 nM) or idarubicin
(25 nM). STF-118804 induced accumulation of a sub-G0 population at 48 hr without antecedent reduction of the S/G2/M population, in contrast to idarubicin.
Data are representative of three independent experiments.
(D) The presence of cleaved PARP (89 kD) was assessed by western blot analysis of lysates from MV411 or SEM leukemia cell lines treated with 100 nM STF-
118804 for 24 (STF 24) or 36 (STF 36) hours, or 25 nM idarubicin for 24 hr (Ida 24). Data are representative of two independent experiments.
(E) Dose-response curve of MV411 cells treated with STF-118804 for 72 hr. Cell viability was measured by a resazurin-based assay (CellTiter-Blue) and a live cell
protease-based assay (CellTiter-Fluor). Data represent three independent experiments performed in triplicate (±SEM).
See also Figure S2.
Chemistry & Biology
Chemical Genetic Discovery of NAMPT InhibitorsNAMPT conferred sensitivity to STF-118804. NAMPT was the
most statistically significant gene to confer sensitivity to STF-
118804 in two independent experimental replicates (Figure 3C,
Mann-Whitney U test). The p values for all genes from the two
replicate screens are given in Table S2.
To validate the screen results, we retested individual shRNAs
against NAMPT for their ability to confer sensitivity to STF-
118804. MV411 cells stably expressing shRNAs targeting
NAMPT exhibited a decrease in STF-118804 IC50 compared to
cells expressing empty vector or a control shRNA (Figure 3D).
The significant decrease in IC50 corresponded to knockdown of
NAMPT expression in the 50%–60% range assessed by real-Chemistry & Biology 20, 1352–136time PCR (Figure 3E), validating the results of the shRNA screen.
Although knockdown of NAMPT by itself can reduce NAD+/
NADH levels, which could potentially explain decreased signal
in a resazurin-based assay, the effect of NAMPT knockdown
was dependent on STF-118804 concentration, which, together
with the results of the functional genomic screen, strongly impli-
cates NAMPT as the molecular target of STF-118804.
The Cytotoxic Effects of STF-118804 Are Exerted
through NAMPT Inhibition
NAMPT is the rate-limiting enzyme in a metabolic salvage
pathway that converts nicotinamide to NAD+ (Figure 4A)3, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1355
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Figure 3. Knockdown of NAMPT Increases Sensitivity to STF-118804
(A) Scheme is shown for ultracomplex shRNA screen in which wild-type MV411 leukemia cells were transduced with a pooled shRNA lentiviral library and
subjected to four rounds of treatment with STF-118804 or four rounds of passage. Frequency of shRNAs in treated and untreated cells was quantified by high-
throughput sequencing.
(B) Counts of individual NAMPT shRNAs (colored dots) in STF-118804 treated versus untreated cells are shown in comparison to distribution of negative control
shRNAs (gray dots). Color scale represents enrichment (blue) or depletion (red) of individual shRNAs in treated versus untreated cells.
(legend continued on next page)
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Figure 4. STF-118804 Specifically Inhibits NAMPT Enzymatic Activity
(A) The salvage (left) and Press-Handler (right) pathways that produce NAD+ from nicotinamide and nicotinic acid, respectively, are shown schematically.
(B) The ability of nicotinic acid (10 mM) to rescue the viability of MV411 cells treated with STF-118804 (left) or idarubicin (right) was assessed at 72 hr of treatment
using CellTiter-Fluor. Data represent three independent experiments performed in triplicate (±SEM).
(C and D) The indicated compounds were tested for inhibition of NAD+ production in a coupled in vitro enzyme assay, shown schematically in (D), in which the
enzymes NAMPT and NMNAT produce NAD+, which is indirectly measured via the formation of the colorimetric indicator Wst-1 formazan that is quantified via
absorbance at 450 nm, as shown in (C). Data represent three independent experiments performed in duplicate (±SEM).
(E and F) The indicated compounds were assessed for inhibition of NAD+ production by NMNAT, which produces NAD+ from the substrates nicotinamide
mononucleotide and ATP, shown schematically in (F). NAD+ production is indirectly measured by formation of NADH, which converts Wst-1 to Wst-1 formazan
that is quantified via absorbance at 450 nm, as shown in (E). STF-118804 did not inhibit NMNAT or other enzymes in the coupled assay including ADH and
diaphorase, thus establishing its specificity for NAMPT, whereas gallotannin (10 mM), a known NMNAT inhibitor, prevented production of NAD+. Data represent
three independent experiments performed in duplicate (±SEM).
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Chemical Genetic Discovery of NAMPT Inhibitors(Belenky et al., 2007). The Preiss-Handler pathway is an alterna-
tive NAD+ biosynthesis pathway that bypasses NAMPT by using
nicotinic acid as a substrate to formNAD+ (Figure 4A). Addition of
nicotinic acid to in vitro viability assays (measured by live cell
protease activity) completely abrogated the toxicity induced in
leukemia cells by STF-118804 but not idarubicin (Figure 4B).(C) Mann Whitney U test p values for enrichment and depletion of STF-118804
independent experimental replicates. Expt, experiment.
(D) STF-118804 dose response is shown for MV411 cells expressing empty vecto
against NAMPT. Data are from five independent experiments (±SEM). Respectiv
(E) Bar graph shows NAMPT transcript levels in cell lines used in (D) as me
(mean ± SEM).
(F and G) STF-118804 dose-response in HEK293T cells transfected with empty
proteins. Cell viability was measured by CellTiter-Blue (F) or CellTiter-Fluor (G). D
See also Table S2.
Chemistry & Biology 20, 1352–136The observed rescue of viability via the Preiss-Handler pathway
suggested that the cytotoxic effects of STF-118804 were due to
depletion of NAD+.
The ability of STF-118804 and analogs to inhibit biosynthesis
of NAD+ from nicotinamide was measured using a coupled
in vitro enzyme assay containing NAMPT and nicotinamide-treated cells in which different genes are knocked down are shown for two
r (pMK1047), shRNAs against Renilla luciferase (Ren), or four different shRNAs
e IC50 and 95% CI values are shown at the right.
asured by quantitative PCR. Data are from four independent experiments
vector (pLX304) or constructs expressing the indicated wt or mutant NAMPT
ata are from three independent experiments performed in triplicate (±SEM).
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Figure 5. STF-118804 Is Highly Efficacious in an Orthotopic Xenograft Model of ALL
(A) Sublethally irradiated (2.5 Gy) NSG mice were transplanted with MV411 cells (5 3 106) modified to constitutively express firefly luciferase. Two
weeks posttransplant, mice were randomized into two groups and treated subcutaneously for 20 days with either a split dose of 50 mg/kg STF-118804 (n = 7) or
vehicle (n = 5).
(B) Bioluminescent images of representative mice show no detectable tumor at day 36 of STF-118804 treatment.
(C) Survival curves for mice treated with STF-118804 (days 14–34) indicate survival extension for an average of 34 days longer than vehicle-treated mice
(p < 0.001, log-rank test).
(D) Bioluminescence quantification shows prolonged suppression of disease for at least 18 days after treatment was discontinued and prevention of relapse in
individual mice. Data represent mean numbers of photons from bioluminescence images for STF-118804 treated (n = 7) and vehicle treated (n = 5) mice (±SEM).
(E) Frequencies of LICs were quantified at day 35 by limit-dilution secondary transplantation and Poisson statistics in mice treated with STF-118804 (n = 3) or
vehicle (n = 3). Mice treatedwith STF-118804 showed a LIC frequency of 1/11,744 (1/4,480–1/30,784), whereasmice treatedwith vehicle showed a LIC frequency
of 1/1,411 (1/600–1/3,320). Error bars indicate SEM.
(F) Bar graph shows significant reduction (p = 0.03, Student’s t test) of leukemia colony-forming cells in bone marrow of mice treated with STF-118804 (n = 8)
versus vehicle (n = 6) at day 35 (mean ± SEM). Whole bone marrow was plated in human methocult without cytokines, which does not support the growth of
endogenous murine progenitors.
See also Figures S3 and S4.
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STF-118804 and its less active analog STF-118791 prevented
NAD+ production (quantified by Wst-1 formazen synthesis), as
did the known NAMPT inhibitor FK866 (all at 10 mM), which
was also cytotoxic to MV411 cells (Figure 1D; Table S1). In
contrast, the analog STF-118803, which lacked inhibitory activity
in cellular assays, did not block NAD+ production in vitro. The
observed reduction in NAD+ biosynthesis was caused by spe-
cific inhibition of NAMPT in the coupled reaction, since none of
the analogs or FK866 inhibited production of NAD+ catalyzed
by the downstream enzyme NMNAT in a parallel in vitro assay
(Figures 4E and 4F). Taken together, the inhibitory activities of
STF-118804 and analogs in NAMPT enzymatic assays, which
correlate with their structure-activity relationship (SAR) in cellular
assays, establish that NAMPT is a molecular target.
Overexpression of NAMPT rendered 293T cells more resistant
to STF-118804 (Figures 3F and 3G), resulting in a higher IC50
(106 nM; 95% confidence interval [CI], 74–151 nM) compared
to control cells (17 nM; 95% CI, 13–23 nM), further confirming1358 Chemistry & Biology 20, 1352–1363, November 21, 2013 ª2013that NAMPT protein levels dictate sensitivity to STF-118804.
Previous studies have shown that resistance to known NAMPT
inhibitors FK866 and CHS-828/GMX1778 (Olesen et al., 2010;
Watson et al., 2009) is conferred by arginine substitutions
(G217R or H191R) in the hydrophobic tunnel in which FK866
binds (Khan et al., 2006). The mutant proteins retain enzymatic
activity but are not inhibited by FK866 or CHS-828/GMX1778
(Olesen et al., 2010; Watson et al., 2009). Similarly, cells overex-
pressing G217R or H191R mutants were completely resistant to
STF-118804 (Figures 3F and 3G), suggesting that it likely binds in
the NAMPT hydrophobic tunnel similarly to FK866. These results
indicate that STF-118804 cytotoxicity is a result of its ability to
inhibit NAMPT and that STF-118804 does not have significant
off-target effects on cell viability.
STF-118804 Is Highly Efficacious In Vivo and Effectively
Depletes Leukemia-Initiating Cells
The potential efficacy of STF-118804 was assessed in an ortho-
topic xenograft model of ALL. Sublethally irradiated NSG miceElsevier Ltd All rights reserved
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express firefly luciferase. Dosing of STF-118804 was initiated
2 weeks posttransplant when MV411 cells had engrafted and
bioluminescent signal was detectable (Figures 5A and 5B).
Although STF-118804 plasma levels rapidly decreased after
subcutaneous, intraperitoneal, or oral delivery (Figure S3A), a
target plasma concentration of 100 nM was maintained for
22 hr by dosing mice subcutaneously twice a day with a 5.5 hr
interval (Figure S3B).
Mice treated with STF-118804 over a 20-day period survived
an average of 34 days longer than vehicle-treated animals (Fig-
ure 5C). During treatment, bioimaging showed regression of
tumor followed by suppression of disease (Figures 5B and 5D).
Regrowth was not apparent, as measured by bioluminescence,
in individual animals until at least 18 days after treatment was
discontinued (Figure 5D). Thus, STF-118804 displayed high effi-
cacy in a xenograft model of ALL.
For assessment of potential effects on leukemia-initiating
cells (LICs), transplanted mice were sacrificed after 20 days
of treatment and analyzed for levels of residual disease. Whole
bone marrow from STF-118804 or vehicle-treated mice was
transplanted into secondary recipients to determine LIC fre-
quency using Poisson statistics. The LIC frequency in STF-
118804-treated mice was significantly lower (8-fold) than that
in vehicle-treated mice, showing that STF-118804 was effective
in reducing leukemia stem cells (LSCs) (Figure 5E). Additionally,
bone marrow from STF-118804-treated mice formed fewer col-
onies in semisolid media that support growth of human cells but
not of endogenous murine progenitors (Figure 5F). These results
indicate that STF-118804 effectively reduces tumor burden and
is also capable of targeting LICs in a xenograft model of high-risk
ALL. STF-118804 was tolerated in the efficacious dose range,
and the absence of adverse physical or pathological effects indi-
cated that toxicity was not limiting in a 20-day study of mock
transplanted mice (Figure S4).
DISCUSSION
We applied a sequential screening approach in a model of high-
risk pediatric B-ALL to identify a distinctive class of NAMPT in-
hibitors. First, a high-throughput cell-based phenotypic screen
identified the highly cytotoxic lead compound STF-118804. Sub-
sequently, an unbiased, ultracomplex, genome-scale shRNA
forward genetic screen identified NAMPT as themolecular target
of STF-118804. The target was then validated, and the lead com-
pound was shown to be efficacious in an orthotopic model.
These results demonstrate that sequential HTS for small mole-
cule identification and shRNA mechanism of action discovery
is an effective approach for drug development, combining the
advantages of phenotypic screening with the power of functional
genomics.
Chemical genetics, or the use of small molecules in shRNA
screening, has been used to study the mechanism of action of
chemotherapeutic agents with known targets (Brummelkamp
et al., 2006; Luo et al., 2008), identify potentially effective drug
combinations (Azorsa et al., 2009; Hassane et al., 2010) and un-
derstand drug resistance (Vidot et al., 2010).We demonstrate the
use of genome-scale chemical genetics to identify the target of
a small molecule discovered in an unbiased cell-based pheno-Chemistry & Biology 20, 1352–136typic screen. Other shRNA proof-of-concept studies have used
low-coverage libraries with drugs at toxic concentrations, which
may bias results by reducing shRNA library complexity.
Ultracomplex (25 shRNAs per gene, thousands of negative
control shRNAs) shRNA library-based screens provide an advan-
tage over other shRNA approaches or target identification
methods, since they provide a way to identify genetic hits with
high statistical confidence and do not require sophisticated
knowledge of chemical SAR, or synthetic chemistry expertise.
NAMPT Inhibitors in Cancer Therapeutics
NAMPT plays a key role in regulating cellular metabolism and
represents an attractive therapeutic target in oncology. NAMPT
overexpression renders cell lines more resistant to chemothera-
peutic agents, whereas knockdown causes sensitization (Yang
et al., 2007). Since cancer cells have altered metabolic needs
and higher rates of NAD+ turnover, their reliance on specific
metabolic pathways is perturbed (Locasale and Cantley, 2010;
Vander Heiden, 2011). Growing evidence indicates that meta-
bolic reprogramming is not simply a result of increased prolifer-
ation associated with cancer cell growth but a direct function of
oncogenes and tumor suppressors and, therefore, a driver of
oncogenesis (Dang, 2012; DeBerardinis et al., 2008; Ward and
Thompson, 2012).
It is unknown why leukemia cells may be particularly suscep-
tible to NAMPT inhibition. One possibility is that NAD+ depletion
by NAMPT inhibitors leads to ATP depletion, and cancer cells
may be susceptible due to high cell metabolism/turnover. How-
ever, this hypothesis is difficult to reconcile with data indicating
that normal cord blood cells proliferating at the same rate as leu-
kemia cells were not as susceptible to STF-118804. Various
mechanisms may account for the cytotoxic effects of NAMPT
inhibition. NAD+ depletion inhibits the NAD+-dependent glyceral-
dehyde 3-phosphate dehydrogenase, thus inhibiting glycolysis
(Tan et al., 2013), on which some cancer cells are preferentially
dependent, even in aerobic conditions. Childhood B-ALL
cells have been shown to undergo a shift in glucose metabolism
that may render them more sensitive to NAMPT inhibition (Boag
et al., 2006).
Other work suggests that NAD+ depletion might have an
impact on the sirtuins, NAD+-dependent protein deacetylases
important in cancer (Cea et al., 2011; Imai et al., 2000). SIRT1,
a member of the sirtuin family, deacetylates and inactivates
p53, which inhibits its tumor suppressor function (Vaziri et al.,
2001). SIRT1 is overexpressed in human CML LSCs, and inhibi-
tion of SIRT1 increases apoptosis in LSCs and reduces their
growth (Li et al., 2012). Deactivation of SIRT1 via NAMPT inhibi-
tion may provide a way to target LSCs and is consistent with
our observation that STF-118804 is effective against LICs in a
xenograft model of high-risk ALL.
STF-118804 represents a distinct class of NAMPT inhibitors
that may improve on previously described inhibitors, given
its substantial preclinical efficacy. CB30865 (Fleischer et al.,
2010), FK866/APO866/WK175 (Wosikowski et al., 2002), and
CHS-828/GMX1778 (Olesen et al., 2008) have been shown to
decrease cellular levels of NAD+. They are active against multiple
tumor types, including leukemia (Nahimana et al., 2009;
Wosikowski et al., 2002). Like STF-118804, they induce
apoptosis (Hasmann and Schemainda, 2003) without causing a3, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1359
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NAMPT knockdown increases sensitivity to CHS-828, whereas
overexpression decreases sensitivity (Watson et al., 2009). How-
ever, NAMPT inhibitors that have entered clinical trials, to date,
have yet to show efficacy (Holen et al., 2008; Hovstadius et al.,
2002). Their clinical effectiveness may have been limited by
poor bioavailability or the selection of an inappropriate indication
and/or patient population. Our studies suggest that high-risk
ALL, colon cancer, and prostate cancer patients may benefit
most.
STF-118804 displays a wide therapeutic index and safety and
efficacy in vivo, and it demonstrates efficacy in depleting LICs.
Its most potent analogs share a meta-substituted pyridine ring
that is also present in other classes of NAMPT inhibitors. How-
ever, our SAR studies indicate that other chemical subgroups
can be substituted at this position. Critical structural features
that distinguish the STF-118804 inhibitor class include a
5-methyl-oxazole ring substructure. Our studies using site-
directed mutant NAMPT proteins suggest that STF-118804
binds in a hydrophobic tunnel between the dimerized enzyme
subunits similar to FK866 (Khan et al., 2006). No inhibitors
have been reported to bind a different surface of NAMPT or
within the known tunnel in a different manner.
NAMPT represents a distint metabolic target in ALL. Relapse
in ALL is thought to be due to the reemergence of a LSC clone.
By targeting bulk leukemia cells as well as LSCs, STF-118804
has the potential to address the major problem of relapse in
high-risk ALL patients. Our studies demonstrate that STF-
118804 has high activity in an in vivo xenotransplant model of
ALL and is a NAMPT inhibitor with demonstrated efficacy in
depleting LICs. Efficacy and safety in this model provide a ratio-
nale for further advancement to lead optimization and clinical
testing and demonstrate that NAD+ biosynthesis inhibitors
have the potential to significantly affect high-risk leukemia.
SIGNIFICANCE
Identifying the target and molecular mechanism of action of
small molecules is a critical challenge in drug discovery. By
using a strategy of sequential unbiased phenotypic small
molecule screens and ultracomplex shRNA library screens,
we identified a distinctive class of highly specific NAMPT
inhibitors active in extending survival and depleting leuke-
mia-initiating cells in acute lymphoblastic leukemia. As
a proof of concept, these studies establish a chemical
genetics approach to drug discovery based on combined
use of cell-based chemical and functional genomic screens
to identify a phenotypically active class of compounds and
subsequently define molecular target and mechanism of
action.
EXPERIMENTAL PROCEDURES
Cell Culture
Human leukemia cell lines were obtained fromATCC or DSMZ, with the excep-
tion of HB (Smith et al., 1989), and maintained at 37C and 5% CO2 in RPMI
1640 supplemented with 10% fetal bovine serum (FBS) and penicillin-strepto-
mycin-glutamine. Cell lines were tested for Mycoplasma by PCR (MD
Bioproducts), and results were verified by IDEXX RADIL Laboratories. Cells
were seeded at a density of 6 3 105 cells per milliliter in all cellular assays.1360 Chemistry & Biology 20, 1352–1363, November 21, 2013 ª2013Human leukemia cell colony-forming assays were performed in semisolid
media (Stem Cell Technologies H4230). Murine progenitors were cultured in
M3630 (Stem Cell Technologies) supplemented with 20 ng/ml stem cell factor
(SCF), 10 ng/ml interleukin-3, 10 ng/ml interleukin-6 (IL-6), and 10 ng/ml gran-
ulocyte/macrophage colony-stimulating factor (Peprotech). Colonies were
enumerated at day 7. Cord blood progenitors were enriched from whole blood
(collected from newborn placenta with informed consent and Stanford Univer-
sity Institutional Review Board [IRB] approval) by Ficoll separation and
depleted of cells expressing lineage-specific antigens, using a lineage deple-
tion antibody cocktail and an AutoMACS magnetic cell separator (Miltenyi
Biotech). Cord blood progenitors were grown in Iscove’s modified Dulbecco’s
medium (GIBCO) containing 20% (v/v) FBS and human cytokines (100 ng/ml
TPO, FLT3, SCF and 20 ng/ml IL-6). Primary patient bonemarrow ALL samples
were obtained at diagnosis after informed consent and IRB approval, and
mononuclear cells were enriched by Ficoll-Hypaque (density, 1.077 g/ml;
GE Healthcare). Cryopreserved cells were thawed; suspended in AIM-V +
AlbuMAX media (Invitrogen), 20% (v/v) FBS, and 2 mM L-glutamine; depleted
of cell debris by Ficoll-Hypaque; and suspended in media.
Chemical Compounds
Chemical compounds were obtained fromChemDiv, Specs, and Chembridge.
STF-118804 was synthesized at ChemDiv. FK-866was acquired fromCayman
Chemicals (Item no. 13287). Gallotannin (Product no. 16201) and nicotinic acid
(Product no. 72309) were purchased from Sigma Aldrich. Compounds were
dissolved in DMSO to stock concentration of 10 mM. For use in cell culture,
compounds were diluted to 2 mM in DMSO and serially diluted in media to
achieve final concentrations. For use in animals, STF-118804 was formulated
in 5% (v/v) DMSO and 20% (w/v) (2-hydroxypropyl)-g-cyclodextrin (Sigma
Aldrich, Product no. H125).
HTS
HTS was performed at the Stanford High-Throughput Biosciences Center
using libraries from ChemDiv, Specs, and Chembridge. Human leukemia cell
lines (HB, RS411, and REH) were plated in clear-bottomed/black-walled
384-well microplates (E&K Scientific) using a Matrix Wellmate (Thermo Scien-
tific). Compounds were added using a robotic pin tool in an automated incu-
bator, and plates were held at 37C/5% CO2 for 48 hr. Cell viability was
assessed 4 hr after the addition of CellTiter-Blue reagent (Promega, Product
no. G8081) in an AnalystGT (Molecular Devices) plate reader at an excitation
of 555 nm and emission of 590 nm.
Cell Viability Assays
Human cell lines or lineage negative cord blood cells were seeded into 96-well
plates (6 3 105 cells per milliliter). Compounds were added in increasing con-
centrations, and cells were incubated at 37C/5% CO2 for 72 hr. To detect
viability, CellTiter-Blue reagent was added at 1:10 dilution, and plates were
incubated for 4 hr at 37/5% CO2 prior to reading on a Flexstation II 384
(Molecular Devices) or a Synergy H1 (BioTek) reader at an excitation of
555 nm and emission detection of 590 nm. Cell viability was also measured
by CellTiter-Fluor (Promega, Product no. G6082). The cell-permeable fluoro-
genic peptide substrate GF-AFC reagent was added at 1:2 dilution, and plates
were incubated for 30 min at 37/5% CO2 prior to reading on a Synergy H1
reader at an excitation of 380 nm and emission detection of 505 nm. Cord
blood cells were enumerated on a hemocytometer, and cell viability was
assessed with trypan blue exclusion dye. Inhibitory concentration (IC50) was
calculated using Prism (Graphpad) software.
Primary patient samples were plated in 96-well plates and treated with
increasing concentrations of STF-118804 for 48 hr at 37C in 5% CO2.
WST-1 reagent (Roche Diagnostics) was added to the culture medium (1:10
dilution), and absorbance was measured at 450 nm using a Bio-Rad model
680 microplate reader. All assays were performed in triplicate. IC50 was calcu-
lated using CalcuSyn version 2.0 software (Biosoft).
Apoptosis Assays
Apoptosis was assessed by flow cytometry using an annexin V-fluorescein
isothiocyanate (FITC) detection kit (BD Biosciences, product no. 556420)
per the manufacturer’s directions. Cells were collected, washed in PBS, and
resuspended in binding buffer (0.1 M HEPES, pH 7.4, 1.4 M NaCl, 25 mMElsevier Ltd All rights reserved
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incubated for 5 min at room temperature. Binding buffer was added, and cells
were analyzed using a FACScan Analyzer (custom Stanford and Cytek), and
data were analyzed using FlowJo v9.4.9.
Cell Cycle Analysis
Cellular DNA content was analyzed via propidium iodide staining. Cells were
collected by centrifugation, resuspended in PBS, and fixed by addition of
cold (20C) 100% ethanol to a final concentration of 70% (v/v). Cells were
washed and resuspended in propidium iodide staining solution (50 mg/ml pro-
pidium iodide [Sigma, product no. P41070], 3.8 mM sodium citrate, and
0.02 mg/ml RNase) and incubated at 4C in the dark. Samples were analyzed
using a FACScan Analyzer, and data were analyzed using FlowJo v9.4.9.
Western Blot Analysis
Pelleted cells were resuspended in SDS lysis buffer (50 mM Tris HCl, pH 6.8,
2% (w/v) SDS, and 10% (v/v) glycerol) prior to electrophoresis in SDS-PAGE,
electrophoretic transfer, and immunoblotting using a PARP-specific antibody
(Cell Signaling Technology, product no. 95425) and rabbit anti-goat horse-
radish peroxidase secondary antibody (Invitrogen, catalog no. 811620).
STF-118804 Sensitivity/Resistance Screen
Four 55,000-element shRNA lentivirus sublibraries targeting a total of 9,300
human genes (25 shRNAs per gene) and containing 500 or more negative
control shRNAs were used to transduce MV411 cells in four pools. After puro-
mycin selection and expansion, MV411 cells stably expressing a sublibrary of
pooled shRNAs were split and subjected to four rounds of treatment with STF-
118804 or mock treatment. For each round, cells were treated with STF-
118804 for 48 hr and then allowed to recover in the absence of compound
for 48 hr. Increasing concentrations of STF-118804 were used for later rounds
of treatment (range, 6–12 nM). A minimum of 5–6 3 107 cells per treatment
condition was maintained at all times to ensure 1,0003 coverage of the
55,000-element sublibrary. Genomic DNA was purified from STF-118804
treated and untreated cells, shRNA sequencing libraries (Table S3) were pre-
pared as described elsewhere (Bassik et al., 2013), and frequencies of shRNA-
encoding cassettes were determined by next-generation sequencing (Illumina
HiSeq). The STF-118804 resistance r conferred by an individual shRNA was
calculated as described elsewhere (Bassik et al., 2013). The set of r values
of all shRNAs for a given gene were compared to the set of r values for the
negative control shRNAs, and the significance by Mann-Whitney U test for
enrichment (resistance) or depletion (sensitivity) was calculated. The STF-
118804 resistance screen was carried out in two independent replicates. To
calculate p values combining data from both experimental replicates, shRNA
phenotypes (STF-118804 resistance r) from the replicates were averaged
before a p value was calculated for each gene (Table S2).
NAMPT shRNA Knockdown and Overexpression
Individual shRNA sequences (Table S4) were cloned into the BstXI site of the
pMK1047 lentiviral vector for stable transduction of MV411 cells, which were
tested for STF-118804 dose response.NAMPT expression in transduced cells
was quantified by real-time PCR (primers given in Table S5). Relative expres-
sion was calculated using the comparative Ct method, with ACTB as a refer-
ence gene.
HEK293T cells were transiently transfected with pLX304 (Addgene) encod-
ing wild-type NAMPT (CCSB-Broad Lentiviral Expression Library, Thermo
Scientific) or mutant derivatives using TurboFect (Thermo Scientific).
pLX304-NAMPT (G217R) and pLX304-NAMPT (H191R) were created by stan-
dard site-directed mutagenesis. Twenty-four hours after transient trans-
fection, cells were seeded in 96-well plates at 10,000 cells per well. Cells
were treated with STF-118804 for 72 hr to measure dose-response using
CellTiter-Blue or CellTiter-Fluor.
Enzyme Assays
We measured the enzymatic activities of NAMPT (code no. CY-1251) and
NMNAT (code no. CY-1252), using in vitro kits (MBL International) and using
the Two-Step Method per manufacturer’s instructions. Compounds, NAMPT
and/or NMNAT enzymes, and their substrates were mixed and incubated at
30C for 1 hr. Reagents for the indicator reaction (Wst-1) were then added,Chemistry & Biology 20, 1352–136and absorbance was read at 450 nm every 5 min at 30C on a Tecan Infinite
M100 multimode plate reader (Tecan).
Animal Studies
Male NSG mice (NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ) 6–8 weeks of age pur-
chased from the Jackson Laboratory were sublethally irradiated (2.5 Gy)
and injected via tail vein with MV411 cells (5 3 106) that were modified to sta-
bly express firefly luciferase via lentivirus infection (Cignal Lenti Positive Con-
trol [luc] SA Biosciences [CLS-PCL-8]). Two weeks posttransplant, mice were
randomized to be treated by subcutaneous injections of STF-118804
(25 mg/kg) or vehicle (20% [w/v] [2-hydroxypropyl]-g-cyclodextrin/5% [v/v]
DMSO) twice daily for 20 consecutive days. Analysis was performed in a non-
blinded fashion, and statistical methods were not used to estimate sample
size. For imaging, mice were injected intraperitoneally with 150 mg/kg D-luci-
feran firefly potassium salt (Xenogen XR-1001) and anesthetized with 3%
isoflurane. Mice were imaged using an IVIS 200 spectrum imaging system
(PerkinElmer), and images were analyzed via Living Image v4.3.1 software
(Caliper LifeSciences). All data collected frommice were included for analysis.
All experiments on mice in this study were performed with the approval of, and
in accordance with, the Stanford University Administrative Panel on Labora-
tory Animal Care.
Limiting Dilution Analysis
Bonemarrow was collected after animals had undergone 20 days of treatment
(35 days posttransplant) with vehicle or STF-118804. Femurs and tibias were
flushed with cold PBS/10% (v/v) FBS, and recovered cells were washed,
counted, resuspended in saline, and held at 4C. Serially diluted bone marrow
cells were injected into the tail vein of sublethally irradiated NSG recipient mice
(n = 3 for each dilution).
NCI-60 Cell Panel
Sensitivity assays of theNCI-60 cancer cell line panel to STF-118804 were per-
formed at the NCI using published methods (http://dtp.nci.nih.gov/branches/
btb/ivclsp.html).
Pharmacokinetics
Blood was collected over a 24-hr period by retro-orbital bleeding of mice
that had been treated with STF-118804. Plasma was collected and stored
at 80C. Plasma concentrations of STF-118804 were quantified by mass
spectrometry.
Toxicity Studies
NSG mice (n = 3 in each group) were injected with saline, STF-118804, or
vehicle subcutaneously twice a day for 10 days. Blood was collected via
retro-orbital bleeding on the first and last days of dosing for pharmacokinetic
analyses. Complete necropsies were performed 1 day after the last dose.
Bone and tissues were fixed in Cal-Ex II (Fisher Scientific) or 10% (v/v)
buffered neutral formalin, respectively; routinely processed for histology;
embedded in paraffin; sectioned; and stained with hematoxylin and eosin
(Histo-Tech Laboratory) for histological analysis. Blood chemistry analysis
was performed in the Stanford Veterinary Service Center’s clinical pathology
laboratory.
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